Corbus制药控股 CRBP 深 沪
等待开盘 06-24 09:30:00 美东时间
8.46
+0.150
+1.81%
华盛通- 最 高8.68
- 今 开8.17
- 成交量 27.29万股
- 最 低 8.05
- 昨 收 8.31
- 总市值 1.57亿
- 52周最高 20.56
- 市盈率 静 --
- 换手率 1.47%
- 52周最低 7.12
- 委 比 98.98%
- 总股本 1852.78万
- 历史最高 323.40
- 量 比 0.81
- 振 幅 7.58%
- 历史最低 3.00
- 每 手 1
- 风险率 2.43%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 美银上调美光科技目标价从950美元升至1500美元，上调迈威尔科技目标价从240美元升至365美元
今日重点评级关注：摩根士丹利：维持杜邦"标配"评级，目标价从52美元升至156美元；蒙特利尔银行：维持Taysha Gene Therapies"跑赢大市"评级，目标价从10美元升至14美元
今天 14:08
美股大行评级 | 花旗维持美光科技"买入"评级！目标价从840美元升至1200美元
今日重点评级关注：Chardan Capital：维持SAB Biotherapeutics"买入"评级，目标价从14美元升至16美元；Northland Capital Markets：维持Applied Digital"跑赢大市"评级，目标价从56美元升至82美元
06-18 19:08
Oppenheimer Maintains Outperform on Corbus Pharmaceuticals, Lowers Price Target to $52
Oppenheimer analyst Jeff Jones maintains Corbus Pharmaceuticals (NASDAQ:CRBP) with a Outperform and lowers the price target from $54 to $52.
06-17 21:29
美股大行评级 | 潜在涨幅99.91%！Tigress Financial上调英伟达目标价至425美元，维持"强力买入"评级
今日重点评级关注：Tigress Financial：维持英伟达"强力买入"评级，目标价从360美元升至425美元；康托·菲茨杰拉德：维持DeFi Development"超配"评级，目标价从6美元升至7美元
05-28 19:00
美股大行评级 | 市值直指1.8万亿美元？瑞银给出美光1600美元天价目标！华尔街绩前集体上调迈威尔科技目标价
今日重点评级关注：Canaccord Genuity：维持Dakota Gold"投机性买入"评级，目标价从16美元升至18美元；瑞杰金融：上调Tectonic Therapeutic评级至"强烈买入"，目标价从76美元升至81美元
05-27 17:33
Corbus Pharmaceuticals Appoints First Chief Business Officer
The latest announcement is out from Corbus Pharmaceuticals ( ($CRBP) ). On May ...
05-21 20:59
Corbus Pharmaceuticals To Discuss Updated Data For Its Phase 1/2 Trial Of CRB-701 Antibody Drug Candidate To Treat Head And Neck Squamous Cell Carcinoma
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP), a clinical-stage company focused on developing promising new therapies in oncology and obesity, today announced that the Company's management team will host a
05-21 20:06
Corbus Pharmaceuticals Adds Independent Director Amid Governance Updates
An announcement from Corbus Pharmaceuticals ( ($CRBP) ) is now available. On Ma...
05-14 20:48
美股大行评级 | 潜在涨幅257.14%！瑞杰金融上调InflaRx目标价至9美元，评级升至"强烈买入"
今日重点评级关注：瑞杰金融：上调InflaRx评级至"强烈买入"，目标价从7美元升至9美元；巴克莱：维持Orchestra BioMed Hldgs"超配"评级，目标价从12美元升至13美元
05-14 14:32
Corbus Pharmaceuticals Appoints Pharma Industry Veteran Brent Pfeiffenberger to Board of Directors
Corbus Pharmaceuticals announced the appointment of Brent Pfeiffenberger, PharmD, MBA, to its Board of Directors. Pfeiffenberger, a seasoned pharma leader with extensive experience in drug development and commercialization, will contribute to advancing Corbus' CRB-701 and CRB-913 programs. CRB-701, a next-generation Nectin-4 ADC, is being evaluated in head and neck squamous cell carcinoma and cervical cancer, with updated data to be presented at ...
05-14 12:00
